PSE
26.11.2018 18:50:10 CET | Business Wire | Press release
Process Systems Enterprise (PSE), the Advanced Process Modelling company, today announced the winners of the prestigious PSE Model-Based Innovation (MBI) Prize for 2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181126005616/en/
PSE, providers of the world-leading gPROMS® modelling platform used for digital design and operations throughout the process industries, awards an annual €3000 winner’s prize and two runners-up prizes of €1000 each for the most innovative use of advanced process modelling techniques in support of published research.
The winners are Johannes Schilling* and Andre Bardow of RWTH Aachen University, and Joachim Gross of Stuttgart University, Germany for their paper Integrated design of ORC process and working fluid using process flowsheeting software and PC-SAFT, published in Proceedings of the IV International Seminar on ORC Power Systems, ORC2017, Italy.
The judges summarised the research as “excellent work investigating the integration of Computer Aided Molecular Design (CAMD) with the gPROMS flowsheeting environment for the integrated design of process and working fluid. Several model libraries in gPROMS ProcessBuilder® were adapted to employ the Variable Molecular Structure Compound feature of the gSAFT® advanced thermodynamic package during process optimisation. The resulting mixed-integer non-linear (MINLP) optimisation simultaneously determined the optimal molecular structure for the working fluid and the corresponding optimal process design”.
Runners up were Seo-Young Park*, Shaun C. Galbraith, Huolong Liu, Bumjoon Cha, Zhuangrong Huang and Seongkyu Yoon of the Department of Chemical Engineering, University of Massachusetts, Lowell, MA; HaeWoo Lee of Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, South Korea; and Thomas O'Connor and Sau Lee of the U.S. Food and Drug Administration, for their paper Prediction of critical quality attributes and optimization of continuous dry granulation process via flowsheet modeling and experimental validation , and Dhia Y. Aqar* of the University of Bradford, UK and Ministry of Oil, Basra, Iraq; and Nejat Rahmanian and Iqbal M. Mujtaba of the University of Bradford, UK for their paper Feasibility of novel integrated dividing-wall batch reactive distillation processes for the synthesis of methyl decanoate . Full details can be found on the PSE website .
The prize is judged by team of leading academics in the field of process systems engineering, Prof. Stratos Pistikopoulos (chair) of Texas A&M Energy Institute, Associate Prof. Michael Georgiadis of the Aristotle University of Thessaloniki, Greece and Prof. Eva Sorensen of University College London.
gPROMS is widely used throughout the chemicals, energy, petrochemical, food and pharmaceuticals sectors, including in some 200 academic organisations. Pieter Schmal, Head of PSE Academic, says “We work closely with academic communities around the world to foster innovation, through our academic programme, the MBI Prize, our Partnerships for Advanced Process Modelling and the PSE Academic Teaching Highway (PATH). We congratulate our winners on the quality of their work.”
For editors
Editors: www.psenterprise.com/news/pr181126
View source version on businesswire.com: https://www.businesswire.com/news/home/20181126005616/en/
Contact:
Kate Burness +44-20-8563-0888 k.burness@psenterprise.com
Link:
Social Media:
https://www.facebook.com//Process-Systems-Enterprise-Limited-PSE-194030330653358/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom